Hemophagocytic Syndrome Clinical Trial
Official title:
A Prospective Clinical Study of Ruxolitinib Phosphate Tablets and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy of T cell lymphoma and NK/T cell lymphoma-associated hemophagocytic syndrome.
This is an open, one-arm, prospective clinical collaborative study. This study is aimed to observe the efficacy and safety of the new combined therapy of Ruxolitinib and Etoposide combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction therapy patients with primary central nervous system lymphoma. A total of 30 patients plan to participate in the study. The primary endpoint is objective remission rate (ORR) of hemophagocytic syndrome, and the secondary endpoints include progression-free survival (PFS) , objective remission rate (ORR) of lymphoma, overall survival (OS), and adverse events(ADR). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01494103 -
Administration of Donor T Cells With the Caspase-9 Suicide Gene
|
Phase 1 | |
| Recruiting |
NCT05882175 -
Prospective Validation of the OHI Index
|
||
| Not yet recruiting |
NCT05353179 -
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
|
Early Phase 1 | |
| Completed |
NCT02113917 -
Children and Adult Hemophagocytic Syndrome (HLHa)
|
||
| Not yet recruiting |
NCT04500886 -
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
|
N/A | |
| Recruiting |
NCT05936086 -
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
|
N/A |